endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

#AS­CO21: As­traZeneca's Lyn­parza earns win in ear­ly breast can­cer pa­tients, crack­ing open post-surgery po­ten­tial

5 years ago
R&D
Pharma

#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

5 years ago
R&D

Bay­er dou­bles down on ra­dio­ther­a­py with ac­qui­si­tions of 2 tiny biotech play­ers built around re­search from Cor­nell

5 years ago
Deals

Lock­ing horns with Ab­b­Vie, J&J boasts post-TNF da­ta for next-gen drug Trem­fya in pso­ri­at­ic arthri­tis

5 years ago
Pharma

Ab­b­Vie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its ex­pan­sion plans

5 years ago
Pharma

Mi­rati wins over a Chi­nese part­ner for KRAS hope­ful, look­ing to tail Am­gen's break­through win

5 years ago
Deals

Alk­er­mes wins FDA nod for com­bo med with an­tipsy­chot­ic olan­za­p­ine — this time with­out the weight gain red flags

5 years ago
FDA+

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

5 years ago
Pharma
FDA+

Bio­haven earns pre­ven­ta­tive nod for mi­graine med Nurtec, snar­ing a much-need­ed leg up over Ab­b­Vie

5 years ago
Pharma
FDA+

No price com­pe­ti­tion in PD-(L)1? That might not last long as EQRx, CStone read out late-stage win for chal­lenger

5 years ago
R&D

Ma­gen­ta's R&D head hits the ex­it just weeks af­ter read­ing out mid-stage da­ta for lead ther­a­py, eye­ing clin­ic for ...

5 years ago
People

FDA adds new 'do not use' note to In­ter­cep­t's Ocali­va la­bel af­ter a slew of side ef­fect re­ports in cir­rho­sis pa­tients

5 years ago
FDA+

Mer­ck KGaA draws the cur­tain on newest lipid nanopar­ti­cle for mR­NA vac­cines, tur­bocharg­ing its an­nu­al ca­pac­i­ty

5 years ago
Coronavirus
Manufacturing

Black­stone en­lists a mur­der­ers' row of ad­vi­sors, in­clud­ing ex-Sanofi CEO Olivi­er Brandi­court, to steer life sci­ences ...

5 years ago
People
Financing

RNA: From the mes­sen­ger to the med­i­cine

5 years ago
Biotech Voices

Ve­rastem wins break­through nod for com­bo ther­a­py in ovar­i­an can­cer; EMA picks up speedy re­view of Bio­Mar­in's gene ...

5 years ago
News Briefing

#AS­CO21: Bris­tol My­ers takes home the win in 1st late-stage study for LAG-3 path­way, set­ting up a US fil­ing

5 years ago
R&D
Pharma

#AS­CO21: Take­da flesh­es out case for oral EGFR drug with fol­low-up piv­otal da­ta in non-small cell lung can­cer

5 years ago
R&D

#AS­CO21: With Bris­tol My­ers set for its own big LAG-3 up­date at AS­CO, Mer­ck touts ear­ly suc­cess for a po­ten­tial ...

5 years ago
R&D

#AS­CO21: EQRx's cheap­er EGFR drug busts Ires­sa in head-to-head test, and a US fil­ing could be right down the road

5 years ago
R&D

#AS­CO21: Mer­ck tacks on ar­mor in ear­ly-line can­cer fight with 2 Keytru­da wins set­ting the tone

5 years ago
R&D

#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks ...

5 years ago
R&D

Ac­celeron un­corks more mid-stage da­ta for PAH drug so­tater­cept as part of the drug's res­ur­rec­tion cam­paign

5 years ago
R&D

An Or­biMed-backed start­up looks to cut ex­cess cor­ti­cos­teroids with mid-stage tests for its lead drug queued up

5 years ago
Financing
Startups
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times